Compare MBAI & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBAI | ELUT |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.1M | 42.5M |
| IPO Year | 2014 | 2020 |
| Metric | MBAI | ELUT |
|---|---|---|
| Price | $2.22 | $0.83 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 18.0K | ★ 97.0K |
| Earning Date | 11-08-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 146.77 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,293,000.00 |
| Revenue This Year | $103.86 | N/A |
| Revenue Next Year | $231.30 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.95 | $0.50 |
| 52 Week High | $10.21 | $1.39 |
| Indicator | MBAI | ELUT |
|---|---|---|
| Relative Strength Index (RSI) | 25.63 | 50.69 |
| Support Level | $1.19 | $0.75 |
| Resistance Level | $3.92 | $0.84 |
| Average True Range (ATR) | 0.28 | 0.06 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 4.46 | 80.91 |
MBody AI Ltd develops enterprise software to deploy and manage autonomous robot workforces for hospitality and gaming operators. The Company's proprietary MBody AI Orchestrator is a hardware-agnostic software platform that manages diverse robot fleets from multiple vendors across sites and use cases under long-term agreements. MBody AI serves Fortune 500 operators as customers.
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.